Anamar Corp
Open
8150 SW 8th St Ste 305
Miami, FL 33144
Anamar Corp, based in Miami, FL, is pioneering the development of a novel medicine aimed at preventing and slowing organ scarring due to fibrotic disease. Their lead compound, AM1476, has received Orphan Drug Designation in the US and EU for the treatment of Systemic Sclerosis.
AM1476 is characterized as a highly selective, peripheral-acting 5HT2B receptor antagonist, offering a unique dual-action potential for treating both skin and lung manifestations of systemic sclerosis. The compound is Phase II ready, supported by Phase I and preclinical proof-of-concept studies.
Generated from the website
Also at this address
See a problem?
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.